aTyr Pharma: Interesting Drug, Difficult Target Market
Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...
Hosted on MSN2d
Cantor Fitzgerald Initiates Coverage of aTyr Pharma (ATYR) with Overweight Recommendation
Fintel reports that on January 6, 2025, Cantor Fitzgerald initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Overweight ...
This Toast Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including ...
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Cantor Fitzgerald
Equities research analysts at Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research report issued to clients and investors on Monday,Briefing.com ...
AZEK (NYSE:AZEK) Raised to “Buy” at Citigroup
AZEK (NYSE:AZEK – Get Free Report) was upgraded by equities research analysts at Citigroup from a “neutral” rating to a “buy” ...
aTyr Pharma initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for ...